The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism

Annals of Surgery

Volumn 240, Issue 2, 2004, Pages 236-242

  Rubino, Francesco ^a   Gagner, Michel ^c,e   Gentileschi, Paolo ^d   Kini, Subhash ^d   Fukuyama, Shoji ^d   Feng, John ^d   Diamond, Ed ^b  

^a IRCAD   (France)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Division of Laparoscopic Surgery   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CORTICOSTERONE; CORTICOTROPIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LEPTIN; NEUROPEPTIDE Y; SOMATOMEDIN C;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT; BYPASS SURGERY; CLINICAL ARTICLE; COMORBIDITY; DIABETES MELLITUS; FEMALE; GLUCOSE METABOLISM; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; MORBID OBESITY; OBESITY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; STOMACH BYPASS; SURGICAL TECHNIQUE;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANASTOMOSIS, ROUX-EN-Y; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLECYSTOKININ; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; HUMANS; LEPTIN; MALE; MIDDLE AGED; OBESITY, MORBID; PREOPERATIVE CARE; PROBABILITY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOMATOMEDINS; STATISTICS, NONPARAMETRIC; WEIGHT LOSS;

EID: 0842303191     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000133117.12646.48     Document Type: Article

References (34)

1. Buchwald H. Overview of bariatric surgery. J Am Coll Surg. 2002;194:367-375.
2. Brolin RE. Update: NIH consensus conference. Gastrointestinal surgery for severe obesity. Nutrition. 1996;12:403-404.
3. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-350.
4. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001;280: E827-E847.
5. Beck B. Neuropeptides and obesity. Nutrition. 2000;16:916-923.
6. Sainsbury A, Cusin I, Rohner-Jeanrenaud F. Adrenalectomy prevents the obesity syndrome produced by chronic central neuropeptide Y infusion in normal rats. Diabetes. 1997;46:209-214.
7. Rohner-Jeanrenaud F, Cusin I, Sainsbury A, et al. The loop system between Neuropeptide Y and Leptin in normal and obese rodents. Horm Metab Res. 1996;28:642-648.
8. Vergoni AV, Bertolini A. Role of melanocortins in the central control of feeding. Eur J Pharmacol. 2000;405:25-32.
9. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999;130:671-680.
10. Fobi MA, Lee H, Holness R, et al. Gastric bypass operation for obesity. World J Surg. 1998;22:925-935.
11. Hickey MS, Pories WJ, MacDonald KG, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg. 1998;227:637-643; discussion 643-644.
12. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural network. Science. 1995;269:546-549.
13. Hwa JJ, Fawzi AB, Graziano MP, et al. Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am J Physiol. 1997;272:R1204-R1209.
14. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540-543.
15. Cases JA, Gabriely I, Ma XH, et al. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes. 2001;50:348-352.
16. Wallace AM, Sattar N, McMillan DC. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res. 1998;4:2977-2979.
17. SchSchols AM, Creutzberg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1220-1226.
18. DeKeyser FG, Leker RR, Weidenfeld J. Activation of the adrenocortical axis by surgical stress: involvement of central norepinephrine and interleukin-1. Neuroimmunomodulation. 2000;7:182-188.
19. Castejon-Casado J, Moreno-Prieto M, Valladares-Mendias JC, et al. Hormonal response to surgical stress in schoolchildren. Eur J Pediatr Surg. 2001;11:44-47.
20. Solano MP, Kumar M, Fernandez B, et al. The pituitary response to ovine corticotropin-releasing hormone is enhanced in obese men and correlates with insulin resistance. Horm Metab Res. 2001;33:39-43.
21. Heiman ML, Ahima RS, Craft LS, et al. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. Endocrinology. 1997;138:3859-3863.
22. Glasow A, Bornstein SR. Leptin and the adrenal gland. Eur J Clin Invest. 2000;30(suppl 3):39-45.
23. Vaisse C, Clement K, Durand E, et al. Melanocortin-4 receptor mutations area frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000;106:253-262.
24. Smith S, Edwards CB, Goodman GN. Changes in diabetic management after Roux en-Y gastric bypass. Obes Surg. 1996;6:345-348.
25. Cowan GS, Buffington CK. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg. 1998;22:987-992.
26. Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg. 1998;22:947-954.
27. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22:936-946.
28. Castagneto M, De Gaetano A, Mingrone G, et al. Normalization of insulin sensitivity in the obese patient after stable weight reduction with biliopancreatic diversion. Obes Surg. 1994;4:161-168.
29. Pories WJ, MacDonald KG, Morgan J, et al. Surgical treatment of obesity and its effect on diabetes: 10-year follow-up. Am J Clin Nutr. 1992;55(suppl):582S-585S.
30. MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1:213-220.
31. Pederson RA. Gastric inhibitory polypeptide. In: Walsh JH, Dockray GJ, eds. Gut Peptides: Biochemistry and Physiology. New York, NY: Raven Press; 1993;217-259.
32. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96:14843-14847.
33. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001;142:521-527.
34. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-307.